Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Treatment With Selpercatinib in RET-Altered Thyroid Cancers

NCT04759911 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT04759911
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04759911 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Treatment With Selpercatinib in RET-Altered Thyroid Cancers
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 26, 2021
Completion date
November 30, 2027
Enrollment
30 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

malignant thyroid gland neoplasm, poorly differentiated thyroid gland carcinoma, recurrent thyroid gland carcinoma, thyroid gland anaplastic carcinoma, thyroid gland medullary carcinoma, thyroid gland papillary carcinoma, thyroid gland squamous cell carcinoma